Vepugratinib not checked
Eli Lilly · LY3866288 · LOXO-435
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total · 2 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- Tested for
- Urinary Bladder Neoplasms (3 trials), Neoplasm Metastasis (2 trials), Carcinoma, Transitional Cell, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3, Ureteral Neoplasms
- Main trialPhase 3
- “The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.”In the company’s words, NCT07218380 on ClinicalTrials.gov
- Other names
- LY3866288 · LOXO-435
Other drugs for Urinary Bladder Neoplasms
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- Disitamab vedotinPfizer · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- CetrelimabJohnson & Johnson (Janssen) · Phase 3
- TAR-200Johnson & Johnson (Janssen) · Phase 3
Coming up3
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- Jul 2028Phase 2 trial completes · ClinicalTrials.gov
- Oct 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Oct 2029 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | |
| Phase 2Not yet recruiting | Jul 2028 | A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer | |
| Phase 1Recruiting | Jun 2027 | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | |
| Phase 1Completed | 2 Dec 2024 | A Study of LY3866288 in Healthy Participants | |
| Phase 1Completed | 3 Jan 2025 | A Study of [14C]-LY3866288 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026